A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy
Latest Information Update: 04 May 2023
At a glance
- Drugs Evinacumab (Primary) ; Evinacumab (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 06 Mar 2023 Results assessing the application of low-density lipoprotein cholesterol polygenic risk score analysis in patients with refractory hypercholesterolemia, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation.
- 04 Apr 2022 Results assessing long-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia, presented at the 71st Annual Scientific Session of the American College of Cardiology.
- 01 Feb 2021 Status changed from active, no longer recruiting to completed.